GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » Cyclically Adjusted PS Ratio

Apellis Pharmaceuticals (FRA:1JK) Cyclically Adjusted PS Ratio : 18.59 (As of May. 22, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Apellis Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-22), Apellis Pharmaceuticals's current share price is €39.04. Apellis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was €2.10. Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 18.59.

The historical rank and industry rank for Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:1JK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 19.49   Med: 29.53   Max: 37.47
Current: 19.49

During the past 11 years, Apellis Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 37.47. The lowest was 19.49. And the median was 29.53.

FRA:1JK's Cyclically Adjusted PS Ratio is ranked worse than
82.45% of 507 companies
in the Biotechnology industry
Industry Median: 5.56 vs FRA:1JK: 19.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Apellis Pharmaceuticals's adjusted revenue per share data of for the fiscal year that ended in Dec23 was €3.064. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.10 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Apellis Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Apellis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 29.00 26.99

Apellis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 26.99 -

Competitive Comparison of Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Apellis Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=39.04/2.1
=18.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apellis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Apellis Pharmaceuticals's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=3.064/129.4194*129.4194
=3.064

Current CPI (Dec23) = 129.4194.

Apellis Pharmaceuticals Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.000 99.070 0.000
201512 0.000 99.792 0.000
201612 0.000 101.863 0.000
201712 0.000 104.011 0.000
201812 0.000 105.998 0.000
201912 0.000 108.420 0.000
202012 2.741 109.897 3.228
202112 0.698 117.630 0.768
202212 0.671 125.222 0.693
202312 3.064 129.419 3.064

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Apellis Pharmaceuticals  (FRA:1JK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Apellis Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals (FRA:1JK) Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Apellis Pharmaceuticals (FRA:1JK) Headlines

No Headlines